FUCIDERM

In local treatment only in localised forms with few lesions. o In local treatment with a combination of general antibiotic therapy adapted in the most extensive forms;

• Disinfection of skin-mucose microbial gites in healthy carriers of staphylococcus, and after staphylococcus, including furunculosis.

The resorption and systemic passage of the antibiotic should not be ruled out in the event of extensive epidermal lesions and leg ulcers.

Skin sensitization may compromise the subsequent use of the same antibiotic by general use.

Bacterial resistance of

Staphylococcus aureus has been reported with topical use of fusid acid.

As with all antibiotics, prolonged or recurrent use of fusid acid may increase the risk of developing antibiotic resistance.

This medicine contains wool fat and ketylic alcohol and may cause local skin reactions (e.g., contact dermatitis).

This pharmaceutical form is not suitable for application to the eye or to the inner face of the eyelids.

Pharmacotherapeutic group

Other topical antibiotics, ATC code: D06AX01.

Fusidic acid is a steroidal antibiotic in the fusidanine family.

Critical concentrations separate sensitive strains from intermediate and resistant strains: S ≤ 2 mg/l and R > 16 mg/l.

The prevalence of acquired resistance may vary with geography and time for some species.

It is therefore useful to have information on the prevalence of local resistance, especially for the treatment of severe infections.

These data can only provide an orientation on the probability of susceptibility of a bacterial strain to this antibiotic.

When the variability of the prevalence of resistance acquired resistance in France is known for a bacterial species, it is indicated in the table below: Categories Frequency of resistance acquired in France (>10%) (extremely values) SENSIBLE Aerobic agents for aerobic agents for aerobic agents for arobic agents for arobic agents for arobic agents for arobic agents for arobic agents for arobic agents for arobic agents for arobic acid for arobic agents.

The frequency of adverse reactions is estimated by a pooled analysis of clinical trial data and spontaneous reports.

Based on the pooled data from clinical studies including 4,724 patients who received fusid acid in cream or ointment, the frequency of adverse reactions is 2.3%.

The most commonly reported adverse reactions are skin reactions of the type pruritus and rash, as well as various limited reactions at the application site, such as pain and irritation; these effects were observed in less than 1% of patients.

Cases of hypersensitivity and oedema of

Quincke were reported.

Adverse reactions are presented by class of organ systems (SOC, Organ System Class ) according to the MedDRA classification and each randomized undesirable effect of the diseased organism, including the low-level, low-level, low-level, low-level, low-level, low-level, low-level, low-level, low-level, low-level, low-level, low-level, low-level, low-level, low-level, low-level, low-level, low-level, low-level, low-level, low-level, low-level, low-level, low-level, low-level.